interferon alfa-n3
Trade name: Alferon-N
Recombinant proteinapproved
Approved
Oct 10, 1989
Interferon alpha-n3 (Alferon-N) is a medication consisting of purified natural human interferon alpha proteins used for the treatment of genital warts. — Wikipedia
Clinical trial activity
6 trials · 7 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000844)
Timeline
1980s
- Oct 10, 1989
Hemispherx Biopharma — Earliest FDA Approval
- Oct 10, 1989
Interferon Sciences — Marketing Organization
- Oct 10, 1989
Hemispherx Biopharma — NDA Secondary Org
- Oct 10, 1989
Hemispherx Biopharma — NDA Organization
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
2000s
- Jan 1, 2004
Hemispherx Biopharma — Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
Interferon alpha/beta receptor agonist
Alpha subunit is binding site
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Approval history
- approvedOct 10, 1989
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaInterferon alpha-n3 ↗
- NCATS47BPR3V3MP ↗
- ChEMBLCHEMBL2109047 ↗
Also known as
- alferon
- alferon ldo
- alferon n gel
- alferon n injection
- interferon alfa-n3
- interferon alfa-n3
- interferon alfa-n3
- interferon alfa-n3
- leukocyte interferon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00215852 | Phase 2 | Jul 1, 2005 | Hemispherx Biopharma |
| NCT00215826 | Phase 2 | Nov 1, 2004 | Hemispherx Biopharma, The Kowloon West Cluster Clinical Research Ethics Committee |
| NCT00000844 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002012 | N/A | Nov 2, 1999 | Interferon Sciences |
| NCT00002018 | N/A | Nov 2, 1999 | Interferon Sciences |
| NCT00002078 | Phase 1 | Nov 2, 1999 | Henry M. Jackson Foundation for the Advancement of Military Medicine, Purdue Pharmaceuticals, United States Army |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hemispherx Biopharma | For profit | 2 | 2 | 1 | 2004 |
| Interferon Sciences | For profit | 2 | 2 | 1 | 1999 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 0 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| Purdue Pharmaceuticals | For profit | 1 | 1 | 1 | 1999 |
| The Kowloon West Cluster Clinical Research Ethics Committee | Academic/Hospital | 1 | 0 | 1 | 2004 |
| United States Army | Government | 1 | 0 | 1 | 1999 |
7 organizations
Page 1 / 1
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Hemispherx Biopharma | For profit | NDA2 | Oct 10, 1989 |
| Hemispherx Biopharma | For profit | NDA | Oct 10, 1989 |
| Interferon Sciences | For profit | MKTG | Oct 10, 1989 |